Cytogenetic Alterations in Multiple Myeloma: Prognostic significance and the choice of Frontline Therapy

FLAVIA STELLA; ESTELA PEDRAZZINI; MARA AGAZZONI; OSCAR BALLESTER; IRMA SLAVUTSKY

CANCER INVESTIGATION

TAYLOR & FRANCIS INC

Lugar: Londres; Año: 2015 vol. 27 p. 1 - 9

0735-7907

Multiple myeloma tumor cells demonstrate multiple and often complex genetic lesions as evaluated by standard cytogenetic/FISH studies. Over the past decade, specific abnormalities have been associated with standard or high-risk clinical behavior and they have become strong prognostic indicators. Further, as evidenced by recent randomized clinical trials, the choice of front-line therapy (transplant vs. no transplant, inclusion of novel drugs such as bortezomib, thalidomide, and lenalidomide) may be able to overcome the adverse effect of high-risk genetic lesions.